MX2018008128A - Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 y gip. - Google Patents
Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 y gip.Info
- Publication number
- MX2018008128A MX2018008128A MX2018008128A MX2018008128A MX2018008128A MX 2018008128 A MX2018008128 A MX 2018008128A MX 2018008128 A MX2018008128 A MX 2018008128A MX 2018008128 A MX2018008128 A MX 2018008128A MX 2018008128 A MX2018008128 A MX 2018008128A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- gip receptor
- persistent conjugate
- triple activator
- activator activating
- Prior art date
Links
- 230000002085 persistent effect Effects 0.000 title abstract 3
- 102000051325 Glucagon Human genes 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title abstract 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 229960004666 glucagon Drugs 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 101100125311 Escherichia coli (strain K12) hyi gene Proteins 0.000 title 1
- 101150039312 GIP gene Proteins 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150191082 | 2015-12-31 | ||
KR20160163737 | 2016-12-02 | ||
PCT/KR2016/015555 WO2017116205A1 (ko) | 2015-12-31 | 2016-12-30 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018008128A true MX2018008128A (es) | 2018-12-06 |
Family
ID=59225193
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018008128A MX2018008128A (es) | 2015-12-31 | 2016-12-30 | Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 y gip. |
MX2018008027A MX2018008027A (es) | 2015-12-31 | 2016-12-30 | Activador triple que activa receptor de glucagon, glp-1 y gip. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018008027A MX2018008027A (es) | 2015-12-31 | 2016-12-30 | Activador triple que activa receptor de glucagon, glp-1 y gip. |
Country Status (32)
Country | Link |
---|---|
US (6) | US10400020B2 (ja) |
EP (3) | EP3398962A4 (ja) |
JP (5) | JP6712323B2 (ja) |
KR (8) | KR20170080521A (ja) |
CN (6) | CN116063453A (ja) |
AU (4) | AU2016382394B2 (ja) |
BR (2) | BR112018013530A2 (ja) |
CA (2) | CA3010265A1 (ja) |
CL (6) | CL2018001776A1 (ja) |
CO (2) | CO2018006982A2 (ja) |
CR (2) | CR20180381A (ja) |
DK (1) | DK3398961T3 (ja) |
DO (2) | DOP2018000157A (ja) |
EA (2) | EA038544B1 (ja) |
EC (2) | ECSP18053055A (ja) |
ES (1) | ES2925098T3 (ja) |
HK (2) | HK1255834A1 (ja) |
HR (1) | HRP20220995T1 (ja) |
HU (1) | HUE059737T2 (ja) |
IL (2) | IL260310B2 (ja) |
MX (2) | MX2018008128A (ja) |
PE (1) | PE20181494A1 (ja) |
PH (2) | PH12018501409A1 (ja) |
PL (1) | PL3398961T3 (ja) |
PT (1) | PT3398961T (ja) |
RS (1) | RS63541B1 (ja) |
SA (2) | SA518391891B1 (ja) |
SG (2) | SG11201805586SA (ja) |
TN (2) | TN2018000231A1 (ja) |
TW (4) | TW202330585A (ja) |
WO (2) | WO2017116204A1 (ja) |
ZA (2) | ZA201804997B (ja) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
AU2015242657B2 (en) * | 2014-03-31 | 2020-05-21 | Hanmi Pharm. Co., Ltd. | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage |
UA126960C2 (uk) | 2014-12-30 | 2023-03-01 | Ханмі Фарм. Ко., Лтд. | Похідна глюкагону |
CN108025041A (zh) | 2015-06-30 | 2018-05-11 | 韩美药品株式会社 | 胰高血糖素衍生物和包含其长效缀合物的组合物 |
AU2016382394B2 (en) | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
KR102005457B1 (ko) | 2016-06-29 | 2019-07-30 | 한미약품 주식회사 | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 |
JP2020506932A (ja) | 2017-02-03 | 2020-03-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続性が増加した生理活性物質の結合体及びその用途 |
US11925691B2 (en) | 2017-02-07 | 2024-03-12 | Hanmi Pharm. Co., Ltd. | Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate |
AU2018219283B2 (en) | 2017-02-08 | 2022-05-19 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
TWI809515B (zh) | 2017-12-21 | 2023-07-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
TWI767095B (zh) | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
CN109239346B (zh) * | 2018-10-31 | 2019-10-11 | 中国药科大学 | 一组代谢标志物在代谢综合征早期诊断方面的应用 |
JP2022515229A (ja) * | 2018-12-21 | 2022-02-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp-1及びgip受容体の全てに活性を有する三重活性体と、インスリンとを含む薬学組成物 |
EP3939990A4 (en) * | 2019-02-15 | 2023-05-24 | Hanmi Fine Chemical Co., Ltd. | NEW INTERMEDIATE USED FOR A BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING IT |
WO2020214012A1 (ko) * | 2019-04-19 | 2020-10-22 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법 |
WO2020214013A1 (ko) * | 2019-04-19 | 2020-10-22 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도 |
CN111944055B (zh) * | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
PT3936142T (pt) * | 2019-06-28 | 2024-03-19 | Hanmi Pharmaceutical Co Ltd | Agonista triplo com atividade em relação a todos os recetores de glucagon, glp-1 e gip para tratamento de doenças hepáticas |
BR112022001081A2 (pt) | 2019-08-19 | 2022-05-24 | Lilly Co Eli | Métodos para produzir análogos de incretina |
JP2022551282A (ja) * | 2019-10-04 | 2022-12-08 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、及びglp-1受容体及びgip受容体二重アゴニストを含む組成物及びその治療学的使用 |
JOP20220110A1 (ar) | 2019-11-11 | 2023-01-30 | Boehringer Ingelheim Int | ناهضات مستقبل npy2 |
AR120714A1 (es) | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
CN111040022B (zh) * | 2019-12-23 | 2021-12-14 | 万新医药科技(苏州)有限公司 | 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂 |
EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF |
KR20210091032A (ko) * | 2020-01-13 | 2021-07-21 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 폐질환의 치료 용도 |
CN115916238A (zh) * | 2020-04-20 | 2023-04-04 | 韩美药品株式会社 | 包含胰高血糖素/GLP-l/GIP受体三重激动剂或其缀合物的高血脂症预防或治疗组合物及其使用方法 |
US20230285583A1 (en) * | 2020-05-22 | 2023-09-14 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-acting conjugate of glucagon, glp-1, and gip trigonal agonist |
CN116209475A (zh) | 2020-07-17 | 2023-06-02 | 韩美药品株式会社 | 包括三重激动长效缀合物或三重激动剂的组合的治疗用途 |
KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
MX2023001599A (es) | 2020-08-14 | 2023-03-07 | Hanmi Pharmaceutical Co Ltd | Composicion farmaceutica que comprende un conjugado de accion prolongada del triple agonista del receptor de glucagon/glp-1/gip. |
EP4197550A1 (en) | 2020-08-14 | 2023-06-21 | Hanmi Pharm. Co., Ltd. | Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors |
KR20220041764A (ko) | 2020-09-25 | 2022-04-01 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도 |
CN116437967A (zh) | 2020-09-25 | 2023-07-14 | 韩美药品株式会社 | 包括对胰高血糖素、glp-1和glp受体全部具有活性的三重激动剂或其缀合物的用于预防或治疗骨病的药物组合物 |
JP2023543043A (ja) | 2020-09-25 | 2023-10-12 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体の持続型結合体の多発性硬化症の治療用途 |
CN115925995A (zh) | 2020-09-30 | 2023-04-07 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
EP4230217A1 (en) * | 2020-10-16 | 2023-08-23 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating lupus-related diseases comprising gip derivative or long-acting conjugate thereof |
EP4230219A1 (en) * | 2020-10-16 | 2023-08-23 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases |
US20230381331A1 (en) * | 2020-10-16 | 2023-11-30 | Hanmi Pharm. Co., Ltd. | Gip derivative, long-acting conjugate thereof, and pharmaceutical composition comprising same |
EP4230218A1 (en) * | 2020-10-16 | 2023-08-23 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating vasculitis |
KR20220050824A (ko) | 2020-10-16 | 2022-04-25 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도 |
US20230391845A1 (en) | 2020-10-30 | 2023-12-07 | Novo Nordisk A/S | Glp-1, gip and glucagon receptor triple agonists |
WO2022117056A1 (zh) * | 2020-12-02 | 2022-06-09 | 南京明德新药研发有限公司 | 含内酰胺修饰的多肽类化合物 |
TW202247856A (zh) | 2020-12-24 | 2022-12-16 | 南韓商韓美藥品股份有限公司 | 新穎之三重升糖素/glp-1/gip受體促效劑及其用途 |
KR20220110117A (ko) * | 2021-01-29 | 2022-08-05 | 한미약품 주식회사 | Gip 유도체 또는 이의 지속형 결합체를 포함하는 폐질환의 예방 또는 치료용 약학적 조성물 |
CA3219647A1 (en) | 2021-05-26 | 2022-12-01 | The United Bio-Technology (Hengqin) Co., Ltd. | Multi agonists and use thereof |
KR20230004135A (ko) | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
WO2023005841A1 (zh) * | 2021-07-30 | 2023-02-02 | 南京明德新药研发有限公司 | 含内酰胺桥的多肽化合物 |
KR20230095665A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 약물 및 이의 용도 |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
WO2023228156A1 (en) * | 2022-05-27 | 2023-11-30 | D&D Pharmatech Inc. | Peptide compositions and methods of use threof |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5476304A (en) | 1977-11-29 | 1979-06-18 | Tokyo Printing Ink Mfg Co Ltd | Ink |
US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
US7084243B2 (en) * | 2000-06-16 | 2006-08-01 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
DE60228972D1 (de) * | 2001-07-31 | 2008-10-30 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
CN1832959A (zh) * | 2003-03-19 | 2006-09-13 | 伊莱利利公司 | 聚乙二醇连接的glp-1化合物 |
WO2005028516A2 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
DK2256134T3 (en) | 2003-11-13 | 2014-02-24 | Hanmi Science Co Ltd | IgG Fc fragment to a drug carrier and process for preparation thereof |
EP2573111A1 (en) * | 2006-04-20 | 2013-03-27 | Amgen Inc. | GLP-1 compounds |
WO2007124045A2 (en) * | 2006-04-20 | 2007-11-01 | Ampla Pharmaceuticals, Inc. | Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity |
US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
US8669228B2 (en) | 2007-01-05 | 2014-03-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
KR20150116465A (ko) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
TWI423821B (zh) | 2007-06-19 | 2014-01-21 | Glucose-containing glucagon-like peptide-1 peptide | |
WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
BRPI0915282A2 (pt) | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
JP5775450B2 (ja) * | 2008-06-17 | 2015-09-09 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | グルカゴン/glp−1受容体コアゴニスト |
KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 pH 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
IN2012DN00377A (ja) | 2009-06-16 | 2015-08-21 | Univ Indiana Res & Tech Corp | |
NZ597981A (en) | 2009-07-13 | 2014-02-28 | Zealand Pharma As | Acylated glucagon analogues |
GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
KR20120128129A (ko) | 2010-01-20 | 2012-11-26 | 질랜드 파마 에이/에스 | 심장 병태의 치료 |
EP2528618A4 (en) * | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
JP5812627B2 (ja) * | 2010-03-10 | 2015-11-17 | 公益財団法人相模中央化学研究所 | 改良Fc受容体およびその製造方法 |
CA2792663A1 (en) | 2010-03-26 | 2011-09-29 | Novo Nordisk A/S | Novel glucagon analogues |
CN103179976A (zh) | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
SG191194A1 (en) * | 2010-12-22 | 2013-07-31 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
US10471127B2 (en) | 2011-05-18 | 2019-11-12 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
KR101502299B1 (ko) | 2011-06-10 | 2015-03-11 | 한미사이언스 주식회사 | 신규한 옥신토모듈린 유도체 및 이를 포함하는 비만 치료용 조성물 |
MY164680A (en) | 2011-06-17 | 2018-01-30 | Hanmi Science Co Ltd | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
KR20140043793A (ko) * | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
JP6324315B2 (ja) | 2011-11-17 | 2018-05-16 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
CN112142855A (zh) | 2012-05-18 | 2020-12-29 | 爱德迪安(北京)生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
WO2013192131A1 (en) * | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
CN104583232B (zh) * | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
PL2864350T3 (pl) * | 2012-06-21 | 2019-01-31 | Indiana University Research And Technology Corporation | Analogi glukagonu wykazujące aktywność wobec receptora GIP |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
AU2013342321B2 (en) | 2012-11-06 | 2017-09-28 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
JP6525456B2 (ja) | 2012-11-20 | 2019-06-05 | メデリス ダイアビーティーズ,エルエルシー | インスリン抵抗性のための改善されたペプチド製剤 |
US10005817B2 (en) * | 2012-11-20 | 2018-06-26 | Eumederis Pharmaceuticals, Inc. | Peptide pharmaceuticals |
ES2653765T3 (es) * | 2012-12-21 | 2018-02-08 | Sanofi | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
EP2986314A4 (en) * | 2013-03-15 | 2016-04-13 | Univ Indiana Res & Tech Corp | PROTOCOLS AND A PROLONGED ACTION |
RS59124B1 (sr) | 2013-04-18 | 2019-09-30 | Novo Nordisk As | Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu |
EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP4212180A1 (en) | 2013-12-18 | 2023-07-19 | The Scripps Research Institute | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
JP6657230B2 (ja) * | 2014-09-24 | 2020-03-04 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | インクレチン−インスリンコンジュゲート |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
UA126960C2 (uk) | 2014-12-30 | 2023-03-01 | Ханмі Фарм. Ко., Лтд. | Похідна глюкагону |
CN108025041A (zh) | 2015-06-30 | 2018-05-11 | 韩美药品株式会社 | 胰高血糖素衍生物和包含其长效缀合物的组合物 |
TW201718629A (zh) | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物 |
EP3384935A4 (en) | 2015-12-02 | 2019-08-21 | Hanmi Pharm. Co., Ltd. | PROTEIN COMPLEX UTILIZING A FATTY ACID DERIVATIVE, AND PROCESS FOR PREPARING THE SAME |
AU2016382394B2 (en) * | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
-
2016
- 2016-12-30 AU AU2016382394A patent/AU2016382394B2/en active Active
- 2016-12-30 EP EP16882157.7A patent/EP3398962A4/en active Pending
- 2016-12-30 BR BR112018013530-5A patent/BR112018013530A2/pt active Search and Examination
- 2016-12-30 CR CR20180381A patent/CR20180381A/es unknown
- 2016-12-30 PE PE2018001233A patent/PE20181494A1/es unknown
- 2016-12-30 CN CN202211234307.9A patent/CN116063453A/zh active Pending
- 2016-12-30 IL IL260310A patent/IL260310B2/en unknown
- 2016-12-30 CN CN202211287482.4A patent/CN116059389A/zh active Pending
- 2016-12-30 JP JP2018534682A patent/JP6712323B2/ja active Active
- 2016-12-30 CA CA3010265A patent/CA3010265A1/en active Pending
- 2016-12-30 TW TW112108994A patent/TW202330585A/zh unknown
- 2016-12-30 SG SG11201805586SA patent/SG11201805586SA/en unknown
- 2016-12-30 PT PT168821569T patent/PT3398961T/pt unknown
- 2016-12-30 WO PCT/KR2016/015554 patent/WO2017116204A1/ko active Application Filing
- 2016-12-30 SG SG11201805573RA patent/SG11201805573RA/en unknown
- 2016-12-30 DK DK16882156.9T patent/DK3398961T3/da active
- 2016-12-30 TW TW105144154A patent/TWI731015B/zh active
- 2016-12-30 BR BR112018013525-9A patent/BR112018013525A2/pt active Search and Examination
- 2016-12-30 HR HRP20220995TT patent/HRP20220995T1/hr unknown
- 2016-12-30 HU HUE16882156A patent/HUE059737T2/hu unknown
- 2016-12-30 JP JP2018534662A patent/JP6712322B2/ja active Active
- 2016-12-30 EP EP21201279.3A patent/EP3985017A1/en active Pending
- 2016-12-30 RS RS20220774A patent/RS63541B1/sr unknown
- 2016-12-30 TN TNP/2018/000231A patent/TN2018000231A1/en unknown
- 2016-12-30 IL IL260318A patent/IL260318B2/en unknown
- 2016-12-30 ES ES16882156T patent/ES2925098T3/es active Active
- 2016-12-30 CR CR20180380A patent/CR20180380A/es unknown
- 2016-12-30 PL PL16882156.9T patent/PL3398961T3/pl unknown
- 2016-12-30 EP EP16882156.9A patent/EP3398961B1/en active Active
- 2016-12-30 EA EA201891360A patent/EA038544B1/ru unknown
- 2016-12-30 CN CN202211234594.3A patent/CN116063454A/zh active Pending
- 2016-12-30 CA CA3010182A patent/CA3010182A1/en active Pending
- 2016-12-30 CN CN201680082352.3A patent/CN108699125B/zh active Active
- 2016-12-30 TW TW111101118A patent/TWI807580B/zh active
- 2016-12-30 MX MX2018008128A patent/MX2018008128A/es unknown
- 2016-12-30 TN TNP/2018/000228A patent/TN2018000228A1/en unknown
- 2016-12-30 EA EA201891359A patent/EA038524B1/ru unknown
- 2016-12-30 AU AU2016382393A patent/AU2016382393B2/en active Active
- 2016-12-30 CN CN202211656375.4A patent/CN115920077A/zh active Pending
- 2016-12-30 TW TW105144155A patent/TWI800478B/zh active
- 2016-12-30 CN CN201680082339.8A patent/CN109071624B/zh active Active
- 2016-12-30 KR KR1020160183499A patent/KR20170080521A/ko active Search and Examination
- 2016-12-30 WO PCT/KR2016/015555 patent/WO2017116205A1/ko active Application Filing
- 2016-12-30 MX MX2018008027A patent/MX2018008027A/es unknown
- 2016-12-30 KR KR1020160183500A patent/KR20170080522A/ko active Search and Examination
-
2018
- 2018-06-25 SA SA518391891A patent/SA518391891B1/ar unknown
- 2018-06-26 SA SA518391903A patent/SA518391903B1/ar unknown
- 2018-06-28 CL CL2018001776A patent/CL2018001776A1/es unknown
- 2018-06-28 DO DO2018000157A patent/DOP2018000157A/es unknown
- 2018-06-29 PH PH12018501409A patent/PH12018501409A1/en unknown
- 2018-06-29 US US16/024,014 patent/US10400020B2/en active Active
- 2018-06-29 US US16/023,994 patent/US10370426B2/en active Active
- 2018-06-29 CL CL2018001795A patent/CL2018001795A1/es unknown
- 2018-06-29 DO DO2018000159A patent/DOP2018000159A/es unknown
- 2018-06-29 PH PH12018501411A patent/PH12018501411A1/en unknown
- 2018-07-04 CO CONC2018/0006982A patent/CO2018006982A2/es unknown
- 2018-07-04 CO CONC2018/0006986A patent/CO2018006986A2/es unknown
- 2018-07-13 EC ECSENADI201853055A patent/ECSP18053055A/es unknown
- 2018-07-13 EC ECSENADI201853053A patent/ECSP18053053A/es unknown
- 2018-07-25 ZA ZA2018/04997A patent/ZA201804997B/en unknown
- 2018-07-25 ZA ZA2018/04998A patent/ZA201804998B/en unknown
- 2018-11-21 HK HK18114910.8A patent/HK1255834A1/zh unknown
-
2019
- 2019-01-14 HK HK19100534.2A patent/HK1258177A1/zh unknown
- 2019-01-31 US US16/263,469 patent/US10981967B2/en active Active
- 2019-03-29 US US16/370,057 patent/US11332508B2/en active Active
- 2019-05-27 KR KR1020190061852A patent/KR102367997B1/ko active IP Right Grant
- 2019-05-27 KR KR1020190061853A patent/KR102401869B1/ko active IP Right Grant
- 2019-06-04 AU AU2019203888A patent/AU2019203888B2/en active Active
- 2019-06-04 AU AU2019203891A patent/AU2019203891B2/en active Active
- 2019-08-29 KR KR1020190106691A patent/KR102179392B1/ko active IP Right Grant
- 2019-08-29 KR KR1020190106690A patent/KR102179391B1/ko active IP Right Grant
-
2020
- 2020-05-29 JP JP2020093904A patent/JP7030894B2/ja active Active
- 2020-05-29 JP JP2020093915A patent/JP2020128428A/ja active Pending
- 2020-07-27 KR KR1020200093189A patent/KR102285377B1/ko active IP Right Grant
- 2020-07-27 KR KR1020200093190A patent/KR102285378B1/ko active IP Right Grant
- 2020-08-05 CL CL2020002034A patent/CL2020002034A1/es unknown
- 2020-08-05 CL CL2020002033A patent/CL2020002033A1/es unknown
-
2021
- 2021-02-26 US US17/187,098 patent/US20210188937A1/en not_active Abandoned
-
2022
- 2022-03-07 CL CL2022000557A patent/CL2022000557A1/es unknown
- 2022-03-07 CL CL2022000558A patent/CL2022000558A1/es unknown
- 2022-03-21 US US17/700,055 patent/US20220213164A1/en active Pending
- 2022-07-07 JP JP2022109549A patent/JP2022130723A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018008128A (es) | Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 y gip. | |
PH12017502393A1 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
PH12016501763A1 (en) | Multispecific antibodies | |
MX2022015755A (es) | Profarmacos de hormona paratiroidea (pth). | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
MX2020003217A (es) | Coagonistas de accion prolongada de los receptores de glucagon y glp-1. | |
WO2017074798A3 (en) | Long-acting co-agonists of the glucagon and glp-1 receptors | |
MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
MX2016014255A (es) | Producto ceramico refractario. | |
MA42889B2 (fr) | Triple activateur activant le récepteur du glucagon, du glp-1 et du gip | |
GB201702889D0 (en) | Mobile software safety application, to create meetings | |
UA104671U (uk) | Застосування яктону як нейропротектора | |
UA101750U (ru) | Применение омега как органопротектора при токсическом гепатите | |
IN2014CH01195A (ja) |